Lv32
320 积分 2023-11-09 加入
Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
1小时前
求助中
Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
2小时前
已完结
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer
6小时前
已完结
GW25-e4362 Relation of high-sensitivity C-reactive protein and homo cysteine levels with recurrence of Paroxysmal atrial fibrillation after catheter ablation of atrial fibrillation
4个月前
已完结
Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment
6个月前
已完结
A Systematic Review of Discrete Choice Experiments in Oncology Treatments
6个月前
已完结
Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis
6个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]
8个月前
已完结
Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making?
1年前
已完结
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
1年前
已完结
皖公网安备34019202002308
